265 related articles for article (PubMed ID: 29285389)
1. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control?
Tamai T; Kumagai K; Sakae H; Onishi H; Tabu K; Tabu E; Muromachi K; Saishoji A; Oda K; Mawatari S; Moriuchi A; Sakurai K; Ido A
Mol Clin Oncol; 2017 Dec; 7(6):1135-1141. PubMed ID: 29285389
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
3. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
5. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
Yao X; Yan D; Zeng H; Liu D; Li H
J Surg Oncol; 2016 May; 113(6):672-7. PubMed ID: 26989044
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolization (TACE) Combined with Sorafenib
Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
[No Abstract] [Full Text] [Related]
8. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.
Fan W; Zhu B; Zheng X; Yue S; Lu M; Fan H; Qiao L; Li F; Yuan G; Wu Y; Zou X; Wang H; Xue M; Li J
J Cancer Res Clin Oncol; 2023 May; 149(5):1873-1882. PubMed ID: 35788728
[TBL] [Abstract][Full Text] [Related]
9. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
[TBL] [Abstract][Full Text] [Related]
10. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.
Li H; Li S; Geng J; Zhao S; Tan K; Yang Z; Feng D; Liu L
Ann Transl Med; 2020 Apr; 8(8):540. PubMed ID: 32411763
[TBL] [Abstract][Full Text] [Related]
11. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.
Peng TR; Wu TW; Wu CC; Chang SY; Chan CY; Hsu CS
Tzu Chi Med J; 2022; 34(2):219-225. PubMed ID: 35465280
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
16. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma.
Wu Y; Qi H; Cao F; Shen L; Chen S; Xie L; Huang T; Song Z; Zhou D; Fan W
Front Pharmacol; 2020; 11():1130. PubMed ID: 32903854
[TBL] [Abstract][Full Text] [Related]
17. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study.
Wu J; Li A; Yang J; Lu Y; Li J
Onco Targets Ther; 2017; 10():2761-2768. PubMed ID: 28603426
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
